Universitaetsklinikum Wuerzburg
Universitaetsklinikum Wuerzburg
Würzburg, Germany10 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Deep Brain Stimulation (DBS) Retrospective Outcomes Study | Dyskinesias, Neurologic Manifestations, Parkinson disease, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, basal ganglia disorder, brain disorder, central nervous system disorder, dystonic disorder, essential tremor, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Recruiting | Not stated | 2026-10-07 | NCT03664609 | |
| Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor | Recruiting | Not stated | 2026-10-01 | NCT07314164 | |
| Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System - RAPID for CNS | Dyskinesias, Neurologic Manifestations, Parkinson disease, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, basal ganglia disorder, brain disorder, central nervous system disorder, dystonic disorder, essential tremor, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Recruiting | Not stated | 2026-09-11 | NCT06553625 | |
| Boston Scientific Registry of Deep Brain Stimulation for Treatment of Essential Tremor (ET) | central nervous system disorder, essential tremor, movement disorder, nervous system disorder | Recruiting | Not stated | 2026-09-11 | NCT04032470 | |
| Vercise™ DBS Dystonia Prospective Study | Dyskinesias, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, dystonic disorder, nervous system disorder | Recruiting | Not stated | 2026-09-11 | NCT02686125 | |
| GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, carcinoma, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, epithelial neoplasm, head and neck squamous cell carcinoma, intestinal disorder, lung disorder, lung neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, primitive neuroectodermal tumor, rectal disorder, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, squamous cell carcinoma | Active, not recruiting | Phase 1 / Phase 2 | 2026-08-04 | NCT04083599 | |
| Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism | Embolism, Embolism and Thrombosis, cardiovascular disorder, lung disorder, pulmonary embolism, respiratory system disorder, vascular disorder | Active, not recruiting | Phase 4 | 2026-07-01 | NCT04790370 | |
| Atrasentan in Patients With IgA Nephropathy | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, autoimmune disease, chronic renal failure syndrome, glomerulonephritis, immune system disorder, kidney disorder, kidney failure, nephritis, urinary system disorder | Active, not recruiting | Phase 3 | 2026-06-04 | NCT04573478 | |
| MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Nutritional and Metabolic Diseases, amyloidosis, cardiomyopathy, cardiovascular disorder, familial amyloid neuropathy, heart disorder, hereditary amyloidosis, hereditary disease, inborn errors of metabolism, metabolic disease, proteostasis deficiencies | Recruiting | Phase 3 | 2026-03-27 | NCT06128629 | |
| Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Active, not recruiting | Phase 2 | 2025-08-01 | NCT03235245 |